Results	O
of	O
an	O
innovative	B:C0005479
bulking	I:C0005479
agent	I:C0005479
in	O
patients	O
with	O
stress	O
urinary	I:C0042025
incontinence	I:C0042025
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

Results	O
of	O
an	O
innovative	O
bulking	I:C0005479
agent	I:C0005479
in	O
patients	O
with	O
stress	B:C0042025
urinary	I:C0042025
incontinence	I:C0042025
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

Results	O
of	O
an	O
innovative	O
bulking	I:C0005479
agent	I:C0005479
in	O
patients	O
with	O
stress	O
urinary	I:C0042025
incontinence	I:C0042025
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	B:C0543467
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	B:C1735321
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	B:C1735321
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	B:C0005479
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	B:C0005479
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	B:C0043210
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	B:C0042025
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	B:C0042025
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
(	O
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
)	O
with	O
an	O
innovative	O
bulking	I:C0005479
material	I:C0005479
(	O
PDMS	O
-	I:C0005479
U	I:C0005479
)	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
(	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
)	O
who	O
are	O
not	O
optimal	O
candidates	O
for	O
mid-urethral	B:C0543467
sling	I:C0543467
surgery	I:C0543467
.	O

A	O
prospective	O
study	O
was	O
performed	O
in	O
women	B:C0043210
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
who	O
,	O
for	O
several	O
reasons	O
,	O
have	O
a	O
relative	O
contraindication	O
for	O
a	O
mid-urethral	O
sling	I:C0543467
procedure	I:C0543467
.	O

A	O
prospective	O
study	O
was	O
performed	O
in	O
women	O
with	O
stress	B:C0042025
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
who	O
,	O
for	O
several	O
reasons	O
,	O
have	O
a	O
relative	O
contraindication	O
for	O
a	O
mid-urethral	O
sling	I:C0543467
procedure	I:C0543467
.	O

A	O
prospective	O
study	O
was	O
performed	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
who	O
,	O
for	O
several	O
reasons	O
,	O
have	O
a	O
relative	O
contraindication	B:C1301638
for	O
a	O
mid-urethral	O
sling	I:C0543467
procedure	I:C0543467
.	O

A	O
prospective	O
study	O
was	O
performed	O
in	O
women	O
with	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
who	O
,	O
for	O
several	O
reasons	O
,	O
have	O
a	O
relative	O
contraindication	O
for	O
a	O
mid-urethral	B:C0543467
sling	I:C0543467
procedure	I:C0543467
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	B:C0042025
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	B:C0042025
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	B:C0543467
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	B:C0332119
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	B:C0038902
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	B:C0332119
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	B:C0524851
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	B:C4053857
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	B:C0043210
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	B:C1301638
for	O
surgery	O
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	B:C0038913
with	O
general	O
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	B:C0002915
or	O
regional	O
anaesthesia	I:C0002911
.	O

These	O
reasons	O
include	O
:	O
(	O
i	O
)	O
recurrent	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
after	O
a	O
prior	O
stress	O
-	I:C0042025
urinary	I:C0042025
incontinence	I:C0042025
surgical	O
procedure	I:C0543467
;	O
(	O
ii	O
)	O
a	O
history	O
of	I:C0332119
oncologic	O
gynaecological	I:C0038902
surgery	I:C0038902
;	O
(	O
iii	O
)	O
a	O
history	O
of	I:C0332119
neurologic	O
disease	I:C0524851
resulting	O
in	O
voiding	O
problems	I:C4053857
;	O
(	O
iv	O
)	O
a	O
maximal	O
flow	O
rate	O
of	O
less	O
than	O
15	O
mL	O
per	O
second	O
or	O
;	O
(	O
v	O
)	O
women	O
with	O
a	O
contraindication	O
for	O
surgery	O
with	O
general	O
or	O
regional	B:C0002911
anaesthesia	I:C0002911
.	O

All	O
women	B:C0043210
were	O
treated	O
with	I:C0332293
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	O
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	O
agent	I:C0005479
that	O
polymerizes	O
in	O
situ	I:C0444498
.	O

All	O
women	O
were	O
treated	B:C0332293
with	I:C0332293
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	O
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	O
agent	I:C0005479
that	O
polymerizes	O
in	O
situ	I:C0444498
.	O

All	O
women	O
were	O
treated	O
with	I:C0332293
peri-urethral	B:C1735321
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	O
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	O
agent	I:C0005479
that	O
polymerizes	O
in	O
situ	I:C0444498
.	O

All	O
women	O
were	O
treated	O
with	I:C0332293
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	B:C0005479
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	O
agent	I:C0005479
that	O
polymerizes	O
in	O
situ	I:C0444498
.	O

All	O
women	O
were	O
treated	O
with	I:C0332293
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	O
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	B:C0005479
agent	I:C0005479
that	O
polymerizes	O
in	O
situ	I:C0444498
.	O

All	O
women	O
were	O
treated	O
with	I:C0332293
peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
consisting	O
of	O
PDMS	O
-	I:C0005479
U	I:C0005479
,	O
a	O
bulking	O
agent	I:C0005479
that	O
polymerizes	O
in	B:C0444498
situ	I:C0444498
.	O

The	O
primary	O
outcome	O
was	O
subjective	O
improvement	O
,	O
defined	O
as	O
"	O
a	B:C4049139
little	I:C4049139
better	I:C4049139
"	O
to	O
"	O
very	O
much	I:C4086947
better	I:C4086947
"	O
on	O
the	O
PGI	O
-	I:C0282574
I	I:C0282574
.	O

The	O
primary	O
outcome	O
was	O
subjective	O
improvement	O
,	O
defined	O
as	O
"	O
a	O
little	I:C4049139
better	I:C4049139
"	O
to	O
"	O
very	B:C4086947
much	I:C4086947
better	I:C4086947
"	O
on	O
the	O
PGI	O
-	I:C0282574
I	I:C0282574
.	O

The	O
primary	O
outcome	O
was	O
subjective	O
improvement	O
,	O
defined	O
as	O
"	O
a	O
little	I:C4049139
better	I:C4049139
"	O
to	O
"	O
very	O
much	I:C4086947
better	I:C4086947
"	O
on	O
the	O
PGI	B:C0282574
-	I:C0282574
I	I:C0282574
.	O

Secondary	O
outcomes	O
included	O
objective	O
cure	O
,	O
disease	O
specific	O
quality	O
of	O
life	O
and	O
adverse	B:C0877248
events	I:C0877248
.	O

There	O
was	O
a	O
statistically	O
significant	O
improvement	O
of	O
all	O
domain	O
scores	O
of	O
the	O
UDI	B:C0282574
-	I:C0282574
6	I:C0282574
,	O
IIQ	O
-	I:C0282574
7	I:C0282574
,	O
and	O
PISQ	O
-	I:C0282574
12	I:C0282574
at	O
6	O
months	O
follow	O
up	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
improvement	O
of	O
all	O
domain	O
scores	O
of	O
the	O
UDI	O
-	I:C0282574
6	I:C0282574
,	O
IIQ	B:C0282574
-	I:C0282574
7	I:C0282574
,	O
and	O
PISQ	O
-	I:C0282574
12	I:C0282574
at	O
6	O
months	O
follow	O
up	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
improvement	O
of	O
all	O
domain	O
scores	O
of	O
the	O
UDI	O
-	I:C0282574
6	I:C0282574
,	O
IIQ	O
-	I:C0282574
7	I:C0282574
,	O
and	O
PISQ	B:C0282574
-	I:C0282574
12	I:C0282574
at	O
6	O
months	O
follow	O
up	O
.	O

Abnormal	B:C0429774
post	I:C0429774
voiding	I:C0429774
residual	I:C0429774
volume	I:C0429774
(	O
>	O
150	O
mL	O
)	O
was	O
the	O
most	O
common	O
adverse	O
event	I:C0877248
(	O
40	O
%	O
)	O
,	O
but	O
persisted	O
in	O
only	O
one	O
patient	O
,	O
based	O
on	O
the	O
patient	O
's	O
preference	O
for	O
a	O
catheter	O
.	O

Abnormal	O
post	I:C0429774
voiding	I:C0429774
residual	I:C0429774
volume	I:C0429774
(	O
>	O
150	O
mL	O
)	O
was	O
the	O
most	O
common	O
adverse	B:C0877248
event	I:C0877248
(	O
40	O
%	O
)	O
,	O
but	O
persisted	O
in	O
only	O
one	O
patient	O
,	O
based	O
on	O
the	O
patient	O
's	O
preference	O
for	O
a	O
catheter	O
.	O

Abnormal	O
post	I:C0429774
voiding	I:C0429774
residual	I:C0429774
volume	I:C0429774
(	O
>	O
150	O
mL	O
)	O
was	O
the	O
most	O
common	O
adverse	O
event	I:C0877248
(	O
40	O
%	O
)	O
,	O
but	O
persisted	O
in	O
only	O
one	O
patient	O
,	O
based	O
on	O
the	O
patient	O
's	O
preference	O
for	O
a	O
catheter	B:C0085590
.	O

peri-urethral	B:C1735321
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	O
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	O
option	O
in	O
women	O
with	O
a	O
relative	O
contra-indication	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	B:C0005479
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	O
option	O
in	O
women	O
with	O
a	O
relative	O
contra-indication	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	O
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	B:C0087111
option	O
in	O
women	O
with	O
a	O
relative	O
contra-indication	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	O
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	O
option	O
in	O
women	B:C0043210
with	O
a	O
relative	O
contra-indication	O
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	O
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	O
option	O
in	O
women	O
with	O
a	O
relative	O
contra-indication	B:C1301638
for	O
mid-urethral	O
sling	I:C0543467
surgery	I:C0543467
.	O

peri-urethral	O
bulking	I:C1735321
injections	I:C1735321
with	O
PDMS	O
-	I:C0005479
U	I:C0005479
is	O
a	O
viable	O
treatment	O
option	O
in	O
women	O
with	O
a	O
relative	O
contra-indication	O
for	O
mid-urethral	B:C0543467
sling	I:C0543467
surgery	I:C0543467
.	O

